DistantNews
Support us
AstraZeneca's oral obesity pill shows encouraging results in clinical trial
🇲🇽 Mexico /Health & Science

AstraZeneca's oral obesity pill shows encouraging results in clinical trial

From El Universal · () Spanish

Translated from Spanish, summarized and contextualized by DistantNews.

At a glance

News Sources not specified New plan
  • AstraZeneca's oral obesity drug, elecoglipron, shows promising weight loss results in a mid-stage clinical trial.
  • The drug, administered once daily, demonstrated weight reductions comparable to other oral GLP-1 receptor agonists and had an acceptable safety profile.
  • Further large-scale Phase 3 trials are needed to confirm long-term efficacy and safety before seeking regulatory approval, as AstraZeneca aims to compete in the growing obesity drug market.

AstraZeneca is making a significant move into the lucrative obesity drug market with its new oral medication, elecoglipron. Early trial results, published in The Lancet, indicate that the drug can help patients achieve substantial weight loss, with the highest dose group losing up to 11.8% of their body weight over 36 weeks. This performance is on par with other leading oral GLP-1 receptor agonists.

The magnitude of weight loss observed with elecoglipron in this study is, in general terms, comparable to the results reported with other oral GLP-1 receptor agonists.

— The studySummarizing the findings of the mid-stage clinical trial published in The Lancet.

The drug's safety and tolerability profile also appears favorable, aligning with expectations for this class of medication. Researchers noted that the observed weight loss is generally comparable to other oral GLP-1 receptor agonists. These encouraging findings support the continuation of elecoglipron's development.

elecoglipron administered orally once a day presented a safety and tolerability profile consistent with this class of drugs that cause spectacular weight losses and reduce appetite.

— The studyDescribing the drug's performance and safety in the randomized study.

However, the study emphasizes the need for larger, longer-term Phase 3 trials. These extensive studies will be crucial to confirm the persistence of the weight loss effects, establish long-term safety, and determine elecoglipron's place among the expanding treatment options for obesity and diabetes. AstraZeneca's entry could intensify competition with established players like Novo Nordisk and Eli Lilly, who already offer oral formulations of their obesity drugs.

Therefore, larger and longer-duration phase 3 trials will be necessary to confirm the persistence of these effects, establish longer-term safety and tolerability, and determine the place of this treatment within the growing range of treatments for obesity and diabetes.

— The studyHighlighting the need for further research before market authorization.
DistantNews Editorial

Originally published by El Universal in Spanish. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog